The long-term objective of our research is to characterize the molecular and genetic role of GCM2 in controlling parathyroid gland development during embryogenesis and parathyroid cell maintenance after birth. Studies in mice have shown that parathyroid formation is under the control of the Gcm2 gene (glial cell missing 2), which encodes a novel transcription factor that is expressed exclusively in the developing and mature parathyroid gland. Studies from our laboratory and by others have shown that genetic mutations that inactivate GCM2 in humans cause hypoparathyroidism, a metabolic disorder characterized by severe hypocalcemia and hyperphosphatemia due to deficiency of parathyroid hormone (PTH). Genetic ablation of Gcm2 in mouse embryos causes a similar phenotype with parathyroid aplasia. These observations establish GCM2 as the master control gene for embryological development of parathyroid glands, but leave unanswered questions about the role of Gcm2 during late gestation and during postnatal life. We hypothesize that expression of Gcm2 in the parathyroid is necessary throughout life to maintain parathyroid cell mass, and that lack of Gcm2 will induce parathyroid cell death. We propose to use mouse models that we have developed that enable us to genetically delete the Gcm2 gene conditionally, in a temporally and spatially controlled manner, to identify the genes that are controlled by Gcm2 action and the effect of loss of Gcm2 on growth and function of mature parathyroid cells. Mice with conditional Gcm2 alleles will also allow us to determine whether ablation of Gcm2 late in life can """"""""rescue"""""""" mice that have parathyroid disorders that replicate the human condition primary hyperparathyroidism.
The specific aims of this proposal are: 1. to characterize our mice with conditional Gcm2 alleles;2. to determine the consequences of timed deletion of Gcm2 on parathyroid cell growth and function in normal mice and mice with parathyroid hyperplasia;and 3. to identify genes that are controlled by Gcm2, using a combination of microarray expression analysis and chromatin immunoprecipitation. Together, these experiments will elucidate the role of GCM2 in regulating parathyroid growth and development across the lifespan, and provide critical new information regarding the genes that are regulated by Gcm2. Ultimately, this information may yield new strategies for regulating parathyroid growth and/or function in patients with parathyroid disorders.

Public Health Relevance

The parathyroid glands synthesize and secrete parathyroid hormone, the principal regulator of bone and mineral metabolism. We now know that embryological development of the parathyroid gland is under the control of a key regulatory gene, GCM2, and that defects in this gene lead to hypoparathyroidism, an endocrine disorder in which blood calcium levels are very low due to absence or deficiency of parathyroid hormone. This research project proposes experiments that will extend our knowledge of the role of GCM2 in controlling parathyroid cell growth and function in health and disease, and which ultimately may have applicability in the treatment of patients who have parathyroid disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK079970-01A2
Application #
7729158
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Malozowski, Saul N
Project Start
2009-07-20
Project End
2011-06-30
Budget Start
2009-07-20
Budget End
2010-06-30
Support Year
1
Fiscal Year
2009
Total Cost
$495,425
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Gordon, Rebecca J; Levine, Michael A (2018) Genetic Disorders of Parathyroid Development and Function. Endocrinol Metab Clin North Am 47:809-823
Vogiatzi, M G; Li, D; Tian, L et al. (2018) A novel dominant COL11A1 mutation in a child with Stickler syndrome type II is associated with recurrent fractures. Osteoporos Int 29:247-251
Vokes, Tamara J; Mannstadt, Michael; Levine, Michael A et al. (2018) Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. J Clin Endocrinol Metab 103:722-731
Li, Dong; Gordon, Christopher T; Oufadem, Myriam et al. (2018) Heterozygous Mutations in TBX1 as a Cause of Isolated Hypoparathyroidism. J Clin Endocrinol Metab 103:4023-4032
Roizen, Jeffrey D; Li, Dong; O'Lear, Lauren et al. (2018) CYP3A4 mutation causes vitamin D-dependent rickets type 3. J Clin Invest 128:1913-1918
Hawkes, Colin Patrick; Li, Dong; Hakonarson, Hakon et al. (2017) CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. J Clin Endocrinol Metab 102:1440-1446
Dhir, Gauri; Li, Dong; Hakonarson, Hakon et al. (2017) Late-onset hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to mutation of SLC34A3/NPT2c. Bone 97:15-19
Li, Dong; Streeten, Elizabeth A; Chan, Alice et al. (2017) Exome Sequencing Reveals Mutations in AIRE as a Cause of Isolated Hypoparathyroidism. J Clin Endocrinol Metab 102:1726-1733
McCormack, Shana E; Li, Dong; Kim, Yeon Joo et al. (2017) Digenic Inheritance of PROKR2 and WDR11 Mutations in Pituitary Stalk Interruption Syndrome. J Clin Endocrinol Metab 102:2501-2507
Mancilla, Edna E; Levine, Michael A; Adzick, N Scott (2017) Outcomes of minimally invasive parathyroidectomy in pediatric patients with primary hyperparathyroidism owing to parathyroid adenoma: A single institution experience. J Pediatr Surg 52:188-191

Showing the most recent 10 out of 26 publications